ArticleVeterinary research communications2026
Assessment of risks associated with dietary administration of antiparasitic drug lufenuron in Nile tilapia Oreochromis niloticus by integrated biomarker response.
Article in Veterinary research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The increasing prevalence of diseases in aquaculture systems has led to an increased use of veterinary medicinal products, but their pathophysiological effects on fish remain poorly understood. The current study assessed the effects of dietary administration of the antiparasitic drug lufenuron (LN) at the recommended dose (5 mg) and overdose (12.5 mg/kg biomass/day) for seven consecutive days on the safety, residue distribution, and biological responses of Nile tilapia Oreochromis niloticus juveniles. The LN caused a dose-dependent decrease in feed intake, survival, and biomass. Plasma biochemical analyses revealed an elevation in glucose, creatinine, aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase levels, and a decrease in calcium, chloride, and acetylcholinesterase in LN-fed O. niloticus. Haematological deviations, and erythrocyte cellular and nuclear alterations, such as vacuolation, crenation, irregularly shaped, teardrop-like cells, micronucleus, and blebbed and notched nuclei, were observed. Oxidative stress biomarkers, including malondialdehyde, ferric-reducing antioxidant power, and total nitric oxide, increased, while glutathione-S-transferase and catalase levels decreased during administration. Nonetheless, these changes were reversible after stopping the dose. The liver was more susceptible to LN, as indicated by the integrated biomarker response assessment. Residue peaks occurred on day 7 of administration in plasma, muscle + skin, liver, and kidney. Following dose suspension, residues declined in both groups but remained detectable until day 35 post-dosing. The withdrawal period for LN in O. niloticus was estimated to be 2 days, considering a maximum residue limit of 1350 µg/kg. Despite short-term adverse effects, dietary administration of LN appears safe for O. niloticus juveniles at the recommended dose.
Indexed as
Identifiers
41569473What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.